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Abstract
Hepatitis B surface antigen (HBsAg) is produced and 
secreted through a complex mechanism that is still 
not fully understood. In clinical fields, HBsAg has long 
served as a qualitative diagnostic marker for hepatitis 
B virus infection. Notably, advances have been made in 
the development of quantitative HBsAg assays, which 
have allowed viral replication monitoring, and there is 
an opportunity to make maximal use of quantitative HB-
sAg to elucidate its role in clinical fields. Yet, it needs to 
be underscored that a further understanding of HBsAg, 
not only from clinical point of view but also from a viro-
logic point of view, would enable us to deepen our in-
sights, so that we could more widely expand and apply 
its utility. It is also important to be familiar with HBsAg 
variants and their clinical consequences in terms of im-
mune escape mutants, issues resulting from overlap 
with corresponding mutation in the P  gene, and detec-
tion problems for the HBsAg variants. In this article, we 
review current concepts and issues on the quantification 
of HBsAg titers with respect to their biologic nature, 
method principles, and clinically relevant topics.
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INTRODUCTION
Hepatitis B virus (HBV) causes a wide range of  clinical 
consequences, from acute and chronic infection to cirrho-
sis and hepatocellular carcinoma, and represents a global 
public health problem[1,2]. Historically, HBV dates to 1967 
when an unknown antigen in Australia was recognized 
to be associated with hepatitis type B, which was later 
referred to as the hepatitis B surface antigen (HBsAg)[3]. 
Since then, HBsAg has served as a qualitative diagnostic 
marker for HBV infection. Notably, advances have been 
made in the development of  quantitative HBsAg assays, 
which have allowed viral replication monitoring. A num-
ber of  clinical studies have evaluated the clinical utility of  
HBsAg and suggested its potential roles. Yet, it needs to 
be underscored that a further understanding of  HBsAg, 
not only from a clinical point of  view but also from a 
virologic point of  view, would enable us to deepen our 
insights, so that we could more widely expand and ap-
ply its utility. Therefore, in this article, we review current 
concepts and issues on the quantification of  HBsAg titers 
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(qHBsAg) with respect to their biologic nature, method 
principles, and clinically relevant topics.
STRUCTURE AND MOLECULAR 
VIROLOGY OF HBsAg
Components of the viral structure
HBV belongs to Hepadnaviridae and is composed of  the 
envelope, core, DNA genome, and viral polymerase. It has 
a circular form of  partially double-stranded DNA and is 
approximately 3200 nucleotides in length[4,5]. A 42-45 nm 
long HBV spherical form (Dane particle), which is the full 
virion with infectivity, can be visualized (Figure 1) under 
electron microscopy. It has two-layered shells. The outer 
shell is the envelope protein referred to as hepatitis B sur-
face (HBs) protein, which is further divided into small, 
middle, and large HBs proteins (SHBs, MHBs and LHBs 
proteins, respectively), and the inner shell is a core protein 
referred to as the hepatitis B core protein in which viral 
polymerase and the HBV genome is enclosed. In addition 
to the abovementioned full virion, smaller non-infectious 
subviral particles are present in the serum; 17-25 nm spheri-
cal particles, mainly composed of  SHBs protein, constitute 
the most abundant form, which is as much as 10 000-fold in 
excess of  the full infectious virion[4,6]. Filamentous (or tubu-
lar) particles are another form, with a 20 nm diameter and 
variable length, and are composed of  SHBs, MHBs, and 
the LHBs protein. The form of  the HBV particles appears 
to be determined by the proportion of  LHBs protein[7]. All 
three forms can be detected in serum with commercial as-
says and are collectively referred to as HBsAg. 
Synthesis and secretion
HBV has four distinct open reading frames (ORFs) that 
encode the envelope, core, polymerase, and X proteins. 
ORF S has three internal AUG codons encoding the 
SHBs, MHBs, and LHBs proteins, which correspond to 
the S, preS2 + S, and preS1 + preS2 + S domains, respec-
tively (Figure 2). These proteins have a common carboxyl 
end but different amino ends[8].
Like all other proteins, mRNA transcription is the 
first event to occur. Two 2.1 kb mRNAs for the M/SHBs 
proteins and a 2.4 kb mRNA for the LHBs protein are 
formed, and take a separate pathway from viral replica-
tion. Diverse transcription factors are involved and act 
on promoters, enhancers, and other regulatory elements, 
such as the glucocorticoid responsive element[9,10]. LHBs 
and M/SHBs expression are thought to be independently 
regulated with different promoters; a typical TATA box 
is present in the LHBs promotor (S promotor Ⅰ, SPI), 
whereas the TATA-less promotor, which usually has mul-
tiple initiation sites, is associated with the M/SHBs pro-
moter, thus accounting for synthesis of  distinct proteins 
from one mRNA. In patients with active viral replication, 
the protein expression pattern shows a predominance of  
the M/SHBs protein in contrast to a predominance of  
the LHBs protein in inactive carriers[11]. After transcrip-
tion, protein synthesis and glycosylation follows at the 
endoplasmic reticulum (ER) membrane resulting in a 226 
amino acid SHBs protein, the MHBs protein with an ad-
ditional 55 amino acids, and the LHBs protein with an ad-
ditional 108-119 amino acids. Although the LHBs mRNA 
includes the M/SHBs sequence, it does not translate into 
the M/SHBs protein, and the ratio between the MHBs 
and SHBs protein is controlled by a complex mechanism, 
which is not fully understood[12]. To form a full virion, a 
mixture of  HBs proteins in a well-balanced ratio is utilized 
to envelop core particles in which SHBs and LHBs pro-
tein are indispensible[13]. The virion is transported to the 
cell membrane through vesicles, and several conditions 
must be satisfied for successful secretion, because excess 
SHBs protein is required, whereas excess LHBs protein 
prevents secretion and causes dilatation of  the ER with a 
ground-glass appearance[14-16].
Function
The primary function of  the HBs protein as a virologic 
structure is to enclose the viral components. It also plays 
a major role in cell membrane attachment to initiate the 
infection process. Several studies have confirmed the idea 
that the peptide in the preS1 domain is essential in this 
process, showing that it specifically binds to the human 
liver plasma membrane and can be inhibited by a mono-
clonal antibody[17,18]. However, participation of  the SHBs 
protein in attachment has also been suggested following 
identification of  hepatocyte-bound endonexin Ⅱ, which 
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Figure 1  Schematic model of hepatitis B surface antigen structure. Three 
forms of hepatitis B surface (HBs) antigen (Dane particle, filamentous particle, 
and spherical particle) are visualized in serum by electron microscopy. These 
are composed of small, middle, and large hepatitis B surface proteins. LHBs: 
Large HBs proteins; MHBs: Middle HBs proteins; SHBs: Small HBs proteins.
2.4 kb mRNA
LHBs protein
2.1 kb mRNA
MHBs protein
SHBs protein
preS1          preS2        S
Figure 2  Schematic presentation of the S/preS1/preS2 gene, RNA tran-
scripts, and translational products. Opening reading frame S has three in-
ternal AUG codons. Transcription to produce the 2.1 kb and 2.4 kb mRNAs first 
occurs after translation into small hepatitis B surface proteins (SHBs), middle 
hepatitis B surface proteins (MHBs), and large hepatitis B surface proteins 
(LHBs) ensues with different promoters.
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specifically binds the SHBs protein[19]. Additionally, from 
the host perspective, the HBs protein has the major anti-
genic components, including the a determinant, which is 
important for host-activated immunity. However, from a 
virologic perspective, it is postulated that excess HBs pro-
tein may divert such neutralizing antibody immune func-
tion away from the infectious virion[20].
QUANTITATIVE HBsAg ASSAYS
Methods to detect HBsAg were first described in the 
1970s using radioimmunoassays and enzyme immunoas-
says[21,22]. Since then, various diagnostic techniques have 
been developed, which are mostly confined to qualitatively 
diagnose HBV in clinical practice. Recently, quantitative 
assay of  HBsAg has been developed, and two commer-
cially available assays will be briefly introduced here.
The Architect HBsAg QT (Abbott Diagnostic, Wi-
esbaden, Germany) is a chemiluminescent microparticle 
immunoassay, which is currently the method most widely 
used in clinical studies[23]. The Architect HBsAg QT assay 
is a two-step immunoassay with flexible assay protocols, 
referred to as Chemiflex, for quantitatively determining 
human serum and plasma HBsAg concentrations. In the 
first step, the sample and hepatitis B surface antigen anti-
body (anti-HBs) coated with paramagnetic microparticles 
are combined. HBsAg present in the sample binds to the 
anti-HBs coated microparticles. After washing, acridini-
um-labeled anti-HBs conjugate is added. Following anoth-
er wash cycle, pre-trigger and trigger solutions are added 
to the reaction mixture. The resulting chemiluminescent 
reaction is measured as relative light units (RLUs). A di-
rect relationship exists between the amount of  HBsAg in 
the sample and the RLUs detected by the Architect Im-
munoassay System optics. The Architect HBsAg is a fully 
automated system and can detect as low as 0.2 ng/mL of  
HBsAg with a dynamic range of  0.05-250.0 IU/mL[24]. 
Elecsys HBsAg Ⅱ (Roche Diagnostics, Indianapolis, 
IN, USA) is another method for quantitatively determin-
ing HBsAg[25]. In the first incubation step, the antigen 
in the sample reacts with two biotinylated monoclonal 
HBsAg-specific antibodies and a monoclonal/polyclonal 
(sheep) HBsAg-specific antibody, labeled with a rutheni-
um complex, to form a sandwich complex. In the second 
step, streptavidin-coated microparticles are added, and the 
complex binds to the solid phase via interaction with bio-
tin and streptavidin. The results are reported as a cutoff  
index (signal sample/cutoff), and the sample is considered 
reactive if  the index is greater than 1.0.
CLINICAL APPLICATION OF 
QUANTITATIVE HBsAg
Correlation with serum HBV DNA
Although measuring serum HBV DNA is the gold stan-
dard for monitoring viral load, it is relatively expensive 
and not yet readily available in some areas. By contrast, 
the technique for detecting qHBsAg is fairly easy and in-
expensive, and the primary aim of  initial clinical studies 
was to determine the relationship between qHBsAg and 
serum HBV DNA (Table 1). In 2004, Deguchi et al[23] first 
reported the clinical significance of  a high qHBsAg in pa-
tients who were hepatitis B e antigen (HBeAg) positive as 
opposed to those with an antibody positive to the hepatitis 
B e antigen (anti-HBe), and that qHBsAg correlated well 
with the serum HBV DNA level (r = 0.862). Although 
there are some contradicting results on whether qHBsAg 
is correlated with serum HBV DNA[26,27], it seems that they 
are correlated based on a number of  studies[28-33]. Further 
studies are required to investigate the possibility of  using 
qHBsAg as an aid, if  not an alternative, for HBV DNA. 
Correlation with covalently closed circular DNA
An important qHBsAg issue is its association with cova-
lently closed circular DNA (cccDNA). cccDNA is a mini-
chromosome and acts as a viral template and replenishing 
pool for maintaining a chronic HBV infection[34]. There-
fore, it is essential to understand the biology of  cccDNA 
when considering HBV therapy. However, to examine 
cccDNA, an invasive procedure is required, and qHBsAg 
has been suggested as a surrogate marker for cccDNA. 
Werle-Lapostolle et al[29] reported a significant decrease in 
cccDNA, qHBsAg, and serum HBV DNA with adefovir 
(ADV) therapy, and that there was a strong correlation be-
tween cccDNA and other variables. This observation was 
supported by subsequent studies; Wursthorn et al[35] and 
Chan et al[36] also showed that cccDNA was significantly 
correlated with qHBsAg, suggesting that serial monitoring 
of  qHBsAg might act as an additional marker to evaluate 
treatment response during antiviral therapy.
Prediction of response to antiviral therapy 
After the accumulation of  data confirming that qHBsAg 
can be utilized as a viral monitor, qHBsAg has been evalu-
ated as a predictor of  virologic response. In a study by 
Chan et al[36] the sensitivity, specificity, and positive and 
negative predictive values for sustained virologic response 
(SVR) in patients treated with pegylated interferon (Peg-
IFN) + lamivudine (LAM) were 86%, 56%, 43%, and 
92%, respectively, with baseline qHBsAg concentrations 
less than 10 000 IU/mL. According to the data of  Manesis 
et al[31] achieving the complete elimination of  HBsAg would 
probably require 10.6 years of  effective LAM therapy or 
5.4 years of  a sustained response to interferon. Recently, 
the clinical usefulness of  on-treatment qHBsAg in patients 
treated with Peg-IFN ± LAM has been suggested in both 
HBeAg positive and negative patients; a decline in qHBsAg 
of  > 1 log IU/mL or specifically 0.5 and 1.0 log IU/mL at 
weeks 12 and 24, respectively, had high predictive value for 
SVR, and on-treatment HBsAg levels could be used as an 
early predictor of  durable off-treatment response to Peg-
IFN-based therapy[32,33,37]. Of  note is a long-term study by 
Marcellin et al[38] in which 35% of  patients who had qHB-
sAg < 1500 IU/mL at week 12 eventually cleared the HB-
sAg by 4 years post-treatment, which supports the clinical 
utility of  qHBsAg. Furthermore, qHBsAg was superior 
to cccDNA and serum HBV DNA for predicting SVR in 
patients undergoing Peg-IFN-based therapy with receiver 
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operating characteristic (ROC) curves of  0.769, 0.734, and 
0.714, respectively[39]. 
MOLECULAR HBsAg VARIANTS
Much of  our understanding of  the biologic nature of  the 
HBs protein has been gathered from various mutation 
and truncated protein experimental models[40,41], and it is 
worthwhile to address the relevance and consequences 
of  HBsAg variants from a clinical point of  view. Besides 
the lack of  HBV proof-reading capacity[42], the develop-
ment of  an HBsAg mutation can be attributed to immune 
pressure from extensive vaccination programs, injections 
of  hepatitis B immunoglobulin (HBIG) following liver 
transplantation, and the overlap with a mutation in the 
corresponding P gene.
Immune escape mutants
Since the introduction of  an extensive vaccination pro-
gram, concerns about HBsAg variants have increased after 
an HBV infection occurred in infants who had received 
an HBV vaccination and who had mounted an adequate 
anti-HBs response. This was presumed to be caused by 
immune selection pressure, because the HBsAg a deter-
minant is the major epitope for HBV vaccination[43,44]. 
Changes in the amino acids within the a determinant, par-
ticularly between 137-147, disable surface antigen domain 
recognition by neutralizing antibodies. Of  importance is 
the G145R mutant, because it is the most common and 
is replication competent with stability[45]. In a Taiwanese 
epidemiological study, it was reported that the prevalence 
of  the a determinant mutation had increased from 7.8% 
to 28.1%, after 15 years of  a universal vaccination pro-
gram[46]. Fortunately, in the following years, neither the 
percentage increase nor any significantly adverse events 
with an outbreak of  HBV infection actually occurred; 
thus, a mass vaccination program is continuing with ad-
equate justification[47]. 
In addition to the extensive vaccination program, the 
wide use of  HBIG following liver transplantation adds 
selection pressure to HBV. Ten of  20 patients who de-
veloped recurrent HBV infection despite hepatitis B im-
munoglobulin prophylaxis had amino acid substitutions 
involving the a determinant, which were mostly absent in 
pretransplantation clones[48]. 
Overlap and mutation in the P gene
A mutation in the P gene from prolonged oral nucleos(t)ide 
therapy can cause an altered sequence in the correspond-
ing S gene due to overlap of  the two genes[49], which is 
summarized in Table 2[50]. The nucleotide at rt204 in the 
P gene is associated with resistance to LAM, telbivudine 
(LdT), and entecavir (ETV), and the rtM204V/I mutation 
typically results in a sI195M, sW196S, sW196L or a termi-
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Table 1  Recent clinical studies with quantification of hepatitis B surface antigen titers in hepatitis B virus infection
Author Antiviral 
therapy
Correlation Prediction Clinical results
Deguchi et al[23] - HBV DNA - qHBsAg is higher in HBeAg(+)
Chen et al[28] - HBV DNA - qHBsAg is higher in HBeAg(+) and high HBV DNA levels, 
whereas qHBsAg is low in low HBV DNA level CHB
Werle-Lapostolle 
et al[29]
ADV cccDNA, HBV 
DNA
- HBsAg and cccDNA decrease with ADV
Kohmoto et al[30] LAM HBV DNA - qHBsAg is helpful for early detection of drug resistant strains
Wursthorn 
et al[35]
Peg-IFN + 
ADV
cccDNA - Peg-IFN + ADV decreases cccDNA and HBsAg, which are 
well correlated
Chan et al[36] Peg-IFN + 
LAM
cccDNA Low baseline qHBsAg can predict SVR Peg-IFN + LAM decreases cccDNA and HBsAg, which are 
well correlated
Manesis et al[31] IFN vs LAM HBV DNA Low baseline qHBsAg can predict SVR IFN induces sharper decrease in qHBsAg than LAM
Wiegand et al[27] FAM ± LAM HBV DNA (not 
correlated)
Decline of qHBsAg can predict HBsAg 
loss
2 log drop to below 100 IU/mL is associated with HBsAg 
clearance
Moucari et al[32] Peg-IFN HBV DNA Early qHBsAg drop can predict SVR qHBsAg may be useful to optimize Peg-IFN therapy
Brunetto et al[33] Peg-IFN ± 
LAM vs LAM
HBV DNA On-treatment qHBsAg decline can 
predict sustained HBsAg loss
qHBsAg < 10 IU/mL at week 48 and 1 log decline predict 
sustained HBsAg clearance to optimize treatment strategy
Lau et al[37] Peg-IFN ± 
LAM
- On-treatment qHBsAg can be used as 
an early predictor of SVR
In HBeAg(+) patients, qHBsAg reduction through weeks 12, 24 
and 48 were higher in patients with HBeAg seroconversion
Marcellin et al[38] Peg-IFN ± 
LAM
- qHBsAg at week 12 can predict long-
term HBsAg clearance
35% of patients who had qHBsAg < 1500 IU/mL at week 12 
cleared up HBsAg by 4 yr post-treatment
Lu et al[39] Peg-IFN ± 
LAM
cccDNA qHBsAg was superior to cccDNA and 
serum HBV DNA in predicting SVR
Area under ROC curve with qHBsAg, cccDNA and HBV DNA 
was 0.769, 0.734, and 0.714, respectively, for predicting SVR
Brunetto et al[65] Peg-IFN ± 
LAM
- On-treatment qHBsAg can be used as 
an early predictor of SVR
On-treatment decline in HBsAg appears to be genotype 
dependent. Genotype B patients showed the most rapid and 
pronounced decline
Hou et al[66] Peg-IFN vs 
LAM
- - Peg-IFN was superior to ADV in HBeAg seroconversion and 
qHBsAg decline in LAM-resistant patients
HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; qHBsAg: Quantification of HBsAg titers; HBeAg: Hepatitis B e antigen; CHB: chronic hepatitis B; 
ADV: Adefovir; LAM: Lamivudine; Peg-IFN: Pegylated interferon; cccDNA: Covalently closed circular DNA; FAM: Famciclovir; SVR: Sustained virologic 
response; ROC: Receiver operating characteristic.
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nal codon in the overlapping S gene[50]. In previous stud-
ies, LAM selected HBsAg mutants with reduced anti-HBs 
binding capacity, and secretion of  HBsAg was prevented 
with a mutant strain due to the stop codon[51,52]. rt181 is 
another important site that confers resistance to ADV 
and/or LAM/LdT. Recently, Warner and Locarnini dem-
onstrated that rtA181T caused a secretory defect and had 
a negative effect on secretion of  the wild-type HBV virion 
because of  a concomitant change in the envelope protein 
at sW172[53]. Similarly, ETV-associated rtI169T/sF161L 
leads to a decrease in HBsAg immunoreactivity[54]. 
The clinical significance of  overlap and a common 
mutational substitution in the S and P gene was further 
extended by Kamili et al[55] who demonstrated a success-
ful experimental infection with the rtV173L, rtL180M, 
and rtM204V HBV mutants that resulted in sE164D and 
sI195M despite high anti-HBs levels in chimpanzees[55]. 
Furthermore, the possibility of  a vice versa phenomenon 
with respect to an extensive vaccination program might be 
postulated in that HBsAg mutants from selection pressure 
might harbor the corresponding P gene mutation, resulting 
in primary resistance to antiviral agents and therapy failure 
with these agents.
Detection and variants of HBsAg
As described above, an HBsAg mutation leads to diverse 
effects, such as decreased secretion and reduced binding 
capacity to anti-HBs. Of  note is that not only a mutation 
in the a determinant but also in the S promoter or a dele-
tion in the preS region can cause such effects[56,57]. These 
effects may hamper the diagnostic performance of  com-
mercial assays, and several reports have pointed to the 
problem of  not being able to detect HBV with an a deter-
minant mutation[58,59]. 
An occult HBV infection is defined as the persistence 
of  the HBV genome in HBsAg negative individuals, and 
one of  the explanations for occult HBV infection is a mu-
tation in HBsAg and undetectability by available assays[60]. 
Both the Architect HBsAg QT and Elecsys HBsAg Ⅱ 
seem to reliably detect HBsAg mutants with high sensi-
tivity and specificity[24,25,61]. However, further studies are 
needed to validate such detection ability, because new or 
complex combinations of  mutations can arise in this era 
of  antiviral agents and extensive vaccination.
FUTURE PERSPECTIVES
Despite progress on qHBsAg, a number of  unanswered 
questions still remain. Precise control mechanisms for 
HBsAg production in HBV are poorly understood. A 
discrepancy between qHBsAg and serum HBV DNA ex-
ists, although a correlation has been documented. Further 
research on the virologic nature of  HBV could answer 
these two questions. Meanwhile, the role of  qHBsAg in 
the clinical field is being actively investigated, especially as 
a predictor to virologic response. Of  particular interest is 
the potential role of  qHBsAg for defining the end point of  
oral antiviral therapy. Current American Association for the 
Study of  Liver Diseases and European Association for the 
Study of  the Liver guidelines with respect to an end point 
for therapy are unsatisfactory, because reversion to HBeAg 
positivity does occur after terminating therapy, and the loss 
of  HBsAg is infrequently encountered[62,63]. In this regard, 
qHBsAg might be particularly helpful in patients with un-
detectable HBV DNA, even with a highly sensitive poly-
merase chain reaction assay[64]. In contrast to undetectable 
HBV DNA, which provides no further information for the 
virologic responders, HBsAg is continuously shed and de-
tected and, based on the observations of  previous studies, 
qHBsAg with serial monitoring in patients with undetect-
able HBV DNA may be utilized to determine the end point 
of  therapy and validate the durability of  antiviral agents. 
CONCLUSION
HBsAg is produced and secreted through a complex me-
chanism that is still not fully understood. Nevertheless, 
quantification of  serum HBsAg is currently available and 
there is an opportunity to make maximal use of  qHBsAg 
to elucidate its role in clinical fields. However, a deep un-
derstanding of  the virology is necessary, and it is also im-
portant to be familiar with HBsAg variants and their clinical 
consequences in terms of  immune escape mutants, issues 
resulting from overlap with corresponding mutation in the 
P gene, and detection problems for the HBsAg variants. 
Unanswered questions need to be resolved through further 
qHBsAg research.
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